Herceptin Eradicates Tumours And May Reduce Mastectomy Need In Women With Inflammatory HER2-Positive Breast Cancer

New data show that the addition of Herceptin® (trastuzumab) to chemotherapy prior to breast cancer surgery (neoadjuvant therapy) completely eradicates tumours in nearly three times as many women with inflammatory HER2-positive breast cancer compared to chemotherapy alone. Inflammatory breast cancer is a rare, but highly aggressive form of the disease - the tumours spread quickly, often leading to the need for full mastectomies, and it has a worse outlook than other breast cancers. [click link for full article]

More: continued here

Filed under: Breast Cancer on September 28th, 2007